Abstract
Our understanding of the genetic contributions to heart muscle disorders has grown tremendously over the past 4 decades. The impact of genotype on cardiomyopathy diagnosis, prognosis, and treatment is well-recognized, although there remains considerable heterogeneity in approach to cardiomyopathy evaluation, access to genetic testing, availability of molecular-based therapies, and representation of diverse populations in genetic databases across the world. In this issue of the Journal of Cardiac Failure, Kubo and Kitaoka 1 Kubo T, Kitaoka H. Genetic testing for cardiomyopathy in Japan 2022: current status and issues of precision medicine. J Card Fail. Google Scholar provide insight into these issues through their appraisal of the current state of genetic evaluation of cardiomyopathies in Japan.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
